162 related articles for article (PubMed ID: 25985569)
1. The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males.
Lou XY; Zhang W; Wang G; Hu DL; Guo D; Tan ZR; Zhou HH; Chen Y; Bao HH
Pharmazie; 2014 Oct; 69(10):775-9. PubMed ID: 25985569
[TBL] [Abstract][Full Text] [Related]
2. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.
Zhang W; Yu BN; He YJ; Fan L; Li Q; Liu ZQ; Wang A; Liu YL; Tan ZR; Fen-Jiang ; Huang YF; Zhou HH
Clin Chim Acta; 2006 Nov; 373(1-2):99-103. PubMed ID: 16784736
[TBL] [Abstract][Full Text] [Related]
3. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
[TBL] [Abstract][Full Text] [Related]
4. Marked Alteration of Rosuvastatin Pharmacokinetics in Healthy Chinese with ABCG2 34G>A and 421C>A Homozygote or Compound Heterozygote.
Wan Z; Wang G; Li T; Xu B; Pei Q; Peng Y; Sun H; Cheng L; Zeng Y; Yang G; Zhu YS
J Pharmacol Exp Ther; 2015 Sep; 354(3):310-5. PubMed ID: 26081159
[TBL] [Abstract][Full Text] [Related]
5. Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans.
Choi JH; Lee MG; Cho JY; Lee JE; Kim KH; Park K
Clin Pharmacol Ther; 2008 Feb; 83(2):251-7. PubMed ID: 17568401
[TBL] [Abstract][Full Text] [Related]
6. [Effect of OATP1B1 521T --> C heterogenesis on pharmacokinetic characterstics of rosuvastatin in Chinese volunteers].
Sui SM; Wen JH; Li XH; Xiong YQ
Yao Xue Xue Bao; 2011 Jun; 46(6):695-700. PubMed ID: 21882531
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study.
Li Y; Jiang X; Lan K; Zhang R; Li X; Jiang Q
Clin Ther; 2007 Oct; 29(10):2194-203. PubMed ID: 18042475
[TBL] [Abstract][Full Text] [Related]
8. Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors.
Choi MK; Shin HJ; Choi YL; Deng JW; Shin JG; Song IS
Xenobiotica; 2011 Jan; 41(1):24-34. PubMed ID: 20946088
[TBL] [Abstract][Full Text] [Related]
9. Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients.
Lee HK; Hu M; Lui SSh; Ho CS; Wong CK; Tomlinson B
Pharmacogenomics; 2013 Aug; 14(11):1283-94. PubMed ID: 23930675
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study.
Li XN; Xu HR; Chen WL; Chu NN; Zhu JR
Clin Ther; 2010 Mar; 32(3):575-87. PubMed ID: 20399994
[TBL] [Abstract][Full Text] [Related]
11. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.
Allred AJ; Bowen CJ; Park JW; Peng B; Williams DD; Wire MB; Lee E
Br J Clin Pharmacol; 2011 Aug; 72(2):321-9. PubMed ID: 21434975
[TBL] [Abstract][Full Text] [Related]
12. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment.
Lee E; Ryan S; Birmingham B; Zalikowski J; March R; Ambrose H; Moore R; Lee C; Chen Y; Schneck D
Clin Pharmacol Ther; 2005 Oct; 78(4):330-41. PubMed ID: 16198652
[TBL] [Abstract][Full Text] [Related]
13. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.
Keskitalo JE; Zolk O; Fromm MF; Kurkinen KJ; Neuvonen PJ; Niemi M
Clin Pharmacol Ther; 2009 Aug; 86(2):197-203. PubMed ID: 19474787
[TBL] [Abstract][Full Text] [Related]
14. Mixed effects of OATP1B1, BCRP and NTCP polymorphisms on the population pharmacokinetics of pravastatin in healthy volunteers.
Lu XF; Zhou Y; Bi KS; Chen XH
Xenobiotica; 2016 Sep; 46(9):841-9. PubMed ID: 26744986
[TBL] [Abstract][Full Text] [Related]
15. Effect of silymarin supplement on the pharmacokinetics of rosuvastatin.
Deng JW; Shon JH; Shin HJ; Park SJ; Yeo CW; Zhou HH; Song IS; Shin JG
Pharm Res; 2008 Aug; 25(8):1807-14. PubMed ID: 18236139
[TBL] [Abstract][Full Text] [Related]
16. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin.
Pasanen MK; Fredrikson H; Neuvonen PJ; Niemi M
Clin Pharmacol Ther; 2007 Dec; 82(6):726-33. PubMed ID: 17473846
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
[TBL] [Abstract][Full Text] [Related]
18. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.
Ho RH; Tirona RG; Leake BF; Glaeser H; Lee W; Lemke CJ; Wang Y; Kim RB
Gastroenterology; 2006 May; 130(6):1793-806. PubMed ID: 16697742
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms in Na+-taurocholate co-transporting polypeptide (NTCP) and ileal apical sodium-dependent bile acid transporter (ASBT) and ethnic comparisons of functional variants of NTCP among Asian populations.
Pan W; Song IS; Shin HJ; Kim MH; Choi YL; Lim SJ; Kim WY; Lee SS; Shin JG
Xenobiotica; 2011 Jun; 41(6):501-10. PubMed ID: 21341987
[TBL] [Abstract][Full Text] [Related]
20. No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.
Keskitalo JE; Kurkinen KJ; Neuvonen M; Backman JT; Neuvonen PJ; Niemi M
Br J Clin Pharmacol; 2009 Aug; 68(2):207-13. PubMed ID: 19694740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
